RTTNews | Sep 8, 2020 10:14AM EDT

10:13 Tuesday, September 8, 2020 (RTTNews.com) - Shares of Heron Therapeutics Inc. (HRTX) are rising over 8% today, after the company announced a successful Type A meeting with the U.S. Food and Drug Administration or FDA in which alignment was reached on the plans for the company to resubmit the New Drug Application or NDA for HTX-011 for the management of postoperative pain in the fourth quarter of this year.

HTX-011 is a dual-acting, fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam. "It is the first and only extended-release local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and opioid use through 72 hours compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control," the company said.

HRTX has been trading in the range of $9.60 - $26.81 for the past one year, and is currently trading at $14.87, up $1.14 or 8.30% in the Tuesday's regular trading session.

Read the original article on RTTNews ( https://www.rttnews.com/3126916/stock-alert-heron-therapeutics-shares-up-8.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved